Canada markets closed

Valneva SE (VLA.VI)

Vienna - Vienna Delayed Price. Currency in EUR
Add to watchlist
10.15-0.62 (-5.71%)
At close: 04:58PM CEST
Full screen
Previous Close10.77
Bid0.00 x 50000
Ask0.00 x 81200
Day's Range10.10 - 10.64
52 Week Range2.06 - 10.64
Avg. Volume14,123
Market Cap914.376M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Motley Fool

    How Pfizer Plans to Unlock Another Mass-Market Vaccine

    As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.

  • GlobeNewswire

    Valneva SE Declaration of shares and voting rights - Interim status at June 22, 2022

    VALNEVA Declaration of shares and voting rights Interim status at June 22, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: June 27, 2022 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on wh

  • GlobeNewswire

    Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

    Saint-Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held yesterday in Paris. Among the adopted resolutions were approval of the 2021 financial statements, delegations for the management board to increase Valneva’s share capital and/or issue financial instruments, and the appointment, fo